PDF(Pubmed)
Abstract：
UNASSIGNED: According to the requirements of the \"Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions\", this health technology assessment provides an evidence-based basis for drug selection and rational clinical use of glucagon-like peptide-1 receptor agonist drugs in medical institutions.
UNASSIGNED: We consult the drug instructions, clinical treatment guidelines and search relevant documents in databases such as China national knowledge infrastructure, Wanfang, PubMed, and government websites such as National Medical Products Administration, Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency to collect and sort out the relevant information of the indications, pharmacological effects, guideline recommendations, drug prices and other information of glucagon-like peptide-1 receptor agonists, using a percentile system systematically evaluate the five dimensions of glucagon-like peptide-1 receptor agonists in terms of pharmaceutical properties, efficacy, safety, economy, and other attributes.
UNASSIGNED: The final scores of the evaluation results from high to low are semaglutide (71.00 points), dulaglutide (68.75 points), liraglutide (67.50 points), exenatide (67.00 points), lixisenatide (63.50 points), polyethylene glycol loxenatide (58.00 points) and benaglutide (49.00 points).
UNASSIGNED: In clinical practice, semaglutide and dulaglutide are the top two drugs that can be used as recommended drugs. This health technology assessment can provide an evidence-based basis for hospital selection and rational use of glucagon-like peptide-1 receptor agonists. Clinicians can rationally choose and use drugs according to the patient\'s conditions and needs.
UNASSIGNED: We consult the drug instructions, clinical treatment guidelines and search relevant documents in databases such as China national knowledge infrastructure, Wanfang, PubMed, and government websites such as National Medical Products Administration, Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency to collect and sort out the relevant information of the indications, pharmacological effects, guideline recommendations, drug prices and other information of glucagon-like peptide-1 receptor agonists, using a percentile system systematically evaluate the five dimensions of glucagon-like peptide-1 receptor agonists in terms of pharmaceutical properties, efficacy, safety, economy, and other attributes.
UNASSIGNED: The final scores of the evaluation results from high to low are semaglutide (71.00 points), dulaglutide (68.75 points), liraglutide (67.50 points), exenatide (67.00 points), lixisenatide (63.50 points), polyethylene glycol loxenatide (58.00 points) and benaglutide (49.00 points).
UNASSIGNED: In clinical practice, semaglutide and dulaglutide are the top two drugs that can be used as recommended drugs. This health technology assessment can provide an evidence-based basis for hospital selection and rational use of glucagon-like peptide-1 receptor agonists. Clinicians can rationally choose and use drugs according to the patient\'s conditions and needs.
摘要：
UNASSIGNED：根据“中国医疗机构药物评估和选择快速指南”的要求，本卫生技术评估为医疗机构的胰高血糖素样肽-1受体激动剂药物选择和临床合理使用提供了循证依据。
未经批准：我们查阅药物说明书，临床治疗指南，并在中国国家知识基础设施等数据库中搜索相关文献，万方,PubMed,以及国家药品监督管理局等政府网站，食品和药物管理局,欧洲药品管理局,和药品医疗器械机构收集和整理适应症的相关信息，药理作用，指导方针建议，胰高血糖素样肽-1受体激动剂的药品价格和其他信息，使用百分位系统系统地评估胰高血糖素样肽-1受体激动剂在药物特性方面的五个维度，功效,安全,经济,和其他属性。
UNASSIGNED：评估结果从高到低的最终得分为semaglutide（71.00分），杜拉鲁肽(68.75分)，利拉鲁肽（67.50分），艾塞那肽（67.00分），利西拉来（63.50分），聚乙二醇洛塞那肽(58.00分)和贝纳鲁肽(49.00分)。
未经批准：在临床实践中，塞马鲁肽和杜拉鲁肽是可以用作推荐药物的前两种药物。本卫生技术评估可为医院选择和合理使用胰高血糖素样肽-1受体激动剂提供循证依据。临床医生可以根据患者的病情和需要合理选择和使用药物。
未经批准：我们查阅药物说明书，临床治疗指南，并在中国国家知识基础设施等数据库中搜索相关文献，万方,PubMed,以及国家药品监督管理局等政府网站，食品和药物管理局,欧洲药品管理局,和药品医疗器械机构收集和整理适应症的相关信息，药理作用，指导方针建议，胰高血糖素样肽-1受体激动剂的药品价格和其他信息，使用百分位系统系统地评估胰高血糖素样肽-1受体激动剂在药物特性方面的五个维度，功效,安全,经济,和其他属性。
UNASSIGNED：评估结果从高到低的最终得分为semaglutide（71.00分），杜拉鲁肽(68.75分)，利拉鲁肽（67.50分），艾塞那肽（67.00分），利西拉来（63.50分），聚乙二醇洛塞那肽(58.00分)和贝纳鲁肽(49.00分)。
未经批准：在临床实践中，塞马鲁肽和杜拉鲁肽是可以用作推荐药物的前两种药物。本卫生技术评估可为医院选择和合理使用胰高血糖素样肽-1受体激动剂提供循证依据。临床医生可以根据患者的病情和需要合理选择和使用药物。
